Evidence map›Paper›PMID 31068801›Full record

ArticleFrontiers in pharmacology2019

Application of

Elias C Padilha, Jianyao Wang, Ed Kerns, Arthur Lee, Wenwei Huang, Jian-Kang Jiang, John McKew, Abdul Mutlib, Rosangela G Peccinini, Paul B Yu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Simple In VitroInternational journal of molecular sciences · 2023
    Article
  2. Article
  3. NOX2 inhibitor GSK2795039 metabolite identification towards drug optimization.Journal of pharmaceutical and biomedical analysis · 2021
    Article
  4. Human osteoarthritis cartilage-derived stromal cells activate joint degeneration through TGF-beta lateral signaling.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Elias C PadilhaDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, United States.
Jianyao WangDepartment of Pharmacokinetics, Dynamics and Metabolism, Discovery Sciences, Janssen Research and Development, Spring House, PA, United States.
Ed KernsDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, United States.
Arthur LeeDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, United States.
Wenwei HuangDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, United States.
Jian-Kang JiangDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, United States.
John McKewDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, United States.
Abdul MutlibFrontage Laboratories, Inc., Department of Drug Metabolism, Exton, PA, United States.
Rosangela G PeccininiDepartment of Natural Active Principles and Toxicology, School of Pharmaceutical Sciences, Universidade Estadual Paulista (UNESP), Araraquara, Brazil.
Paul B YuDivision of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.
Philip SandersonDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, United States.
Xin XuDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, United States.

Funding

Pharmacokinetics and Drug MetabolismZIATR000369 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI XU, XIN · 2018 to 2025
$27.3M
BMP Inhibitors to Treat Fibrodysplasia Ossificans ProgressivaZIATR000008 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI SANDERSON, PHILIP · 2015 to 2021
$10.7M
Novel probes of BMP and TGF-beta signaling and functionR01AR057374 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI YU, PAUL B · 2010 to 2023
$4.5M
NIAMS NIH HHS R01 AR057374
6 · The paper itself

Abstract

Currently no approved treatment exists for fibrodysplasia ossificans progressiva (FOP) patients, and disease progression results in severe restriction of joint function and premature mortality. LDN-193189 has been demonstrated to be efficacious in a mouse FOP disease model after oral administration. To support species selection for drug safety evaluation and to guide structure optimization for back-up compounds,

Indexed as

aldehyde oxidasefibrodysplasia ossificans progressivametabolite identificationreactive metabolitestructure optimization

Identifiers

PMID31068801
PMCPMC6491728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.